{
    "organizations": [],
    "uuid": "a19b6d5f89551b208673e42f1ba3eb89213f093c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-company/brief-vtv-therapeutics-announces-company-will-pre-specify-new-subgroup-with-the-fda-idUSASC0A16A",
    "ord_in_thread": 0,
    "title": "BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - vTv Therapeutics Inc:\n* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE\n* VTV THERAPEUTICS INC - SUBGROUP OF MILD ALZHEIMERâ€™S PATIENTS IN PART A OF PHASE 3 STEADFAST STUDY DEMONSTRATED POSITIVE BENEFIT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:37:00.000+03:00",
    "crawled": "2018-05-10T17:52:37.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "vtv",
        "therapeutic",
        "inc",
        "vtv",
        "therapeutic",
        "announces",
        "company",
        "new",
        "subgroup",
        "fda",
        "report",
        "phase",
        "part",
        "b",
        "result",
        "june",
        "vtv",
        "therapeutic",
        "inc",
        "subgroup",
        "mild",
        "alzheimer",
        "patient",
        "part",
        "phase",
        "steadfast",
        "study",
        "demonstrated",
        "positive",
        "benefit",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}